Inozyme Pharma, Inc.

Inozyme Pharma is a clinical-stage biopharmaceutical company, with approximately 50 employees based in Boston. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.

1. SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding Inozyme Pharma, Inc.Aug 14, 2025
2. SCHEDULE 13G/A - filed by Rock Springs Capital Management LP regarding Inozyme Pharma, Inc.Aug 13, 2025
3. SCHEDULE 13G/A - filed by Adage Capital Management, L.P. regarding Inozyme Pharma, Inc.Aug 12, 2025
4. 15-12G filingJul 11, 2025
5. 4 filingJul 3, 2025